Foghorn Therapeutics - FHTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $13.00
  • Forecasted Upside: 108.00%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.25
▲ +0.08 (1.30%)

This chart shows the closing price for FHTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Foghorn Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FHTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FHTX

Analyst Price Target is $13.00
▲ +108.00% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Foghorn Therapeutics in the last 3 months. The average price target is $13.00, with a high forecast of $20.00 and a low forecast of $6.00. The average price target represents a 108.00% upside from the last price of $6.25.

This chart shows the closing price for FHTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 polled investment analysts is to moderate buy stock in Foghorn Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/18/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/17/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
5/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
4/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
4/10/2024WedbushReiterated RatingOutperform ➝ Outperform$13.00Low
11/13/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$10.00 ➝ $6.00Low
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
6/28/2023The Goldman Sachs GroupLower Target$21.00 ➝ $19.00Low
5/9/2023HC WainwrightLower Target$25.00 ➝ $20.00Low
4/25/2023BMO Capital MarketsLower Target$20.00 ➝ $19.00Low
4/25/2023WedbushLower Target$20.00 ➝ $15.00Low
3/28/2023Bank of AmericaInitiated CoverageBuy$10.00Low
3/10/2023WedbushLower TargetOutperform$25.00 ➝ $20.00Low
3/10/2023HC WainwrightReiterated RatingBuy$25.00N/A
1/5/2023BMO Capital MarketsInitiated CoverageOutperform$20.00N/A
11/21/2022Morgan StanleyLower TargetEqual Weight$15.00 ➝ $14.00Low
8/23/2022WedbushLower Target$25.00Low
8/23/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$25.00 ➝ $15.00Low
8/10/2022HC WainwrightLower Target$25.00 ➝ $18.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$30.00 ➝ $21.00Low
5/23/2022Morgan StanleyLower TargetOverweight$26.00 ➝ $25.00Medium
5/20/2022HC WainwrightLower TargetBuy$25.00 ➝ $18.00High
3/17/2022WedbushReiterated RatingOutperform$32.00High
3/11/2022HC WainwrightReiterated RatingBuy$25.00Low
12/15/2021Morgan StanleyBoost TargetOverweight$23.00 ➝ $26.00Medium
11/22/2021HC WainwrightInitiated CoverageBuy$25.00High
3/23/2021Morgan StanleyLower TargetOverweight$24.00 ➝ $23.00High
11/17/2020Morgan StanleyInitiated CoverageOverweight$24.00High
11/17/2020WedbushInitiated CoverageOutperform$24.00High
11/17/2020CowenInitiated CoverageOutperformHigh
11/17/2020The Goldman Sachs GroupInitiated CoverageBuy$27.00High
(Data available from 7/16/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/19/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
2/17/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/18/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/17/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/17/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/16/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Foghorn Therapeutics logo
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $6.25
Low: $5.97
High: $6.36

50 Day Range

MA: $5.68
Low: $4.80
High: $6.25

52 Week Range

Now: $6.25
Low: $2.70
High: $9.97

Volume

95,829 shs

Average Volume

131,807 shs

Market Capitalization

$266.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Foghorn Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Foghorn Therapeutics in the last year: HC Wainwright, Morgan Stanley, and Wedbush.
View the latest analyst ratings for FHTX.

What is the current price target for Foghorn Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Foghorn Therapeutics in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 108.0%. HC Wainwright has the highest price target set, predicting FHTX will reach $20.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $6.00 for Foghorn Therapeutics in the next year.
View the latest price targets for FHTX.

What is the current consensus analyst rating for Foghorn Therapeutics?

Foghorn Therapeutics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for FHTX.

What other companies compete with Foghorn Therapeutics?

How do I contact Foghorn Therapeutics' investor relations team?

The company's listed phone number is 617-586-3100 and its investor relations email address is [email protected]. The official website for Foghorn Therapeutics is foghorntx.com. Learn More about contacing Foghorn Therapeutics investor relations.